An early rise in urine N-telopeptide predicts the growth response of normal prepubertal short children to growth hormone therapy

M. Phillip*, E. Hershkovitz, Y. Limoni, E. Leiberman, O. Belotserkovsky, A. Douvdevani, D. Weber

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

The effects of growth hormone (GH) therapy on biochemical markers of bone turnover were investigated in 11 short prepubertal children without GB[ deficiency by measuring serum osteocalcin, a marker for bone formation, and urinary concentrations of pyridinium crosslinked amino acids of collagen (PCL), and the peptide-bound pyridinoline residue N-telopeptide (NT), which are specific markers for bone resorption, GH treatment for three months increased bone turnover in this group of children: urinary PCL concentrations increased from 69 ± 6.2 to 114 ± 9.3 nmol/mmol Cr (p < 0.01), and urinary NT levels increased from 512 ± 65 to 766 ± 74 pmol BCE/μmol Cr (p = 0.058). Serum osteocalcin concentrations increased from 13.64 ± 2.57 ng/ml to 26.45 ± 1.39 ng/ml (p < 0.01). The increment in 12-hour urinary concentrations of PCL was highly correlated with the increment in 12-hour urinary NT levels (r = 0.92, p < 0.01), Stepwise multiple regression analysis revealed that the urinary concentrations of NT after 3 months of GH therapy were the best predictor of growth after 12 months of treatment (r = 0.78, F = 7.9, p = 0.037).

Original languageEnglish
Pages (from-to)519-521
Number of pages3
JournalJournal of Pediatric Endocrinology and Metabolism
Volume9
Issue number5
DOIs
StatePublished - 1996
Externally publishedYes

Keywords

  • Bone turnover
  • Growth hormone
  • Growth response
  • N-telopeptide
  • Osteocalcin
  • Pyridinium cross-links

Fingerprint

Dive into the research topics of 'An early rise in urine N-telopeptide predicts the growth response of normal prepubertal short children to growth hormone therapy'. Together they form a unique fingerprint.

Cite this